NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…
Articles by Natasha Yetman
Medicare Paid Doctors $90 Billion in 2013, up 17%
NEW YORK (Reuters)—Medicare, the government-run health insurance program for elderly and disabled Americans, paid physicians $90 billion in 2013, up 17% from $77 billion in 2012, U.S. healthcare officials reported on Monday. Physician payments accounted for less than one-fifth of Medicare’s 2013 net outlays of $492 billion, which rose from $466 billion in 2012. Payments to…
Telemedicine Company Wins Order Putting Texas Remote Treatment Rule on Hold
(Reuters)—Patients in Texas can continue to receive remote diagnoses and treatment after telemedicine company Teladoc Inc won a preliminary court order blocking a new state rule requiring doctors to meet patients first. The ruling in Austin federal court on Friday came the same day that Teladoc filed its public registration with the U.S. Securities and…
Isometric Exercise May Immediately Reduce Pain of Patellar Tendinopathy
NEW YORK (Reuters Health)—Volleyball players with patellar tendinopathy reported an immediate easing of their pain after isometric exercise, and the effect persisted for 45 minutes after the intervention, a new study has found. In contrast, isotonic exercise appeared to diminish the athletes’ pain to a lesser degree, and the effect did not last at the…
Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA
NEW YORK (Reuters Health)—A number of recent studies support last year’s update of 2010 treat-to-target recommendations for rheumatoid arthritis (RA), according to the international task force that revised them. Dr. Josef S. Smolen from Medical University of Vienna, Austria, and colleagues updated their 2010 advice based on systematic literature reviews and expert opinion. They left…
AstraZeneca Hit after Psoriasis Drug Linked to Suicide Fears
LONDON (Reuters)—AstraZeneca’s hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal…
- « Previous Page
- 1
- …
- 95
- 96
- 97